Cutler Group LP Fate Therapeutics Inc Call Options Transaction History

Cutler Group LP

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Oct 26, 2021	BUY	$59.27 - $95.73 $71,124 - $114,876	1,200 Added 400.0%	1,500 $0
Q1 2021 Apr 26, 2021	SELL	$72.16 - $117.4 $108,240 - $176,100	-1,500 Reduced 83.33%	300 $0
Q4 2020 Jan 21, 2021	SELL	$38.09 - $100.95 $38,090 - $100,950	-1,000 Reduced 35.71%	1,800 $34,000
Q3 2020 Oct 27, 2020	BUY	$30.41 - $40.5 $63,861 - $85,050	2,100 Added 300.0%	2,800 $11,000
Q2 2020 Jul 22, 2020	SELL	$20.21 - $35.23 $99,029 - $172,626	-4,900 Reduced 87.5%	700 $1,000
Q1 2020 May 07, 2020	BUY	$17.28 - $31.88 $63,936 - $117,956	3,700 Added 194.74%	5,600 $35,000
Q4 2019 Feb 06, 2020	BUY	$13.39 - $20.73 $25,441 - $39,387	1,900 New	1,900 $4,000
Q3 2019 Oct 28, 2019	SELL	$15.47 - $22.5 $21,658 - $31,500	-1,400 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$15.61 - $20.44 $3,122 - $4,088	-200 Reduced 12.5%	1,400 $1,000
Q1 2019 May 10, 2019	BUY	$13.15 - $18.71 $7,890 - $11,226	600 Added 60.0%	1,600 $1,000
Q4 2018 Feb 05, 2019	SELL	$11.48 - $16.98 $11,480 - $16,980	-1,000 Reduced 50.0%	1,000 $0
Q3 2018 Nov 07, 2018	BUY	$8.75 - $16.29 $7,000 - $13,032	800 Added 66.67%	2,000 $5,000
Q2 2018 Aug 10, 2018	BUY	$9.16 - $13.48 $10,992 - $16,176	1,200 New	1,200 $0

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.